MSLN and neoplasm: The effectiveness of tumor-targeted anti-mesothelin chimeric antigen receptor (CAR)-T cells is enhanced by pre-conditioning the tumor microenvironment (TME) with folate receptor (FR)-specific CAR-T cells.